​Clinical Trials

Breast Cancer Risk and Genetic Testing 

• BRCA1 and BRCA2 are human genes that belong to a class of genes known as tumor suppressors. Mutation of these genes has been linked to hereditary breast and ovarian cancer.
• A woman’s risk of developing breast and/or ovarian cancer is greatly increased if she inherits a deleterious (harmful) BRCA1 or BRCA2 mutation.
• Genetic tests are available to check for BRCA1 and BRCA2 mutations. A blood sample is required for these tests, and genetic counseling is recommended before and after the tests.
• If a harmful BRCA1 or BRCA2 mutation is found, several options are available to help a person manage their cancer risk.

Source: cancer.gov
​

New class of drugs: poly (ADP-ribose) polymerase, or PARP inhibitors 

• Early promising results on phase I and Phase II of triple negative breast cancer patients enrolled in clinical trials.

• A shrinking of the tumor is also reported in a patient enrolled in phase III trial

​BSI-201 (one of the new class of drug), in combination with conventional chemotherapy, significantly improved overall and progression-free survival in women with metastatic triple-negative breast cancer, compared with chemotherapy alone.

Source: MD Anderson’s Department of Breast Medical Oncology’s report
3D Mamography advances Breast Cancer Detection
 
3D Mamograohy offers enhanced image quality and the ability to view through  and around dense breast tissue. It reveals the inner structures of the breast tissue, by layers and from various angles and can reveal hiddden tumors especially in women who have dense breast tissue. Women who previous mamograms have demonstrated dense breast tissue may especially benefit  from 3D mamography. Source : Texas Health Presbyterian Hospital Plano’s